269 Refractory Chronic Urticaria Treated with Omalizumab

作者
Martinez Saenz,Ramírez Del Pozo,Lopez Tiro JJ,Javier Goméz Vera
出处
期刊:World Allergy Organization Journal [Elsevier BV]
卷期号:5: S88-S88
标识
DOI:10.1097/01.wox.0000412026.08889.ad
摘要

BACKGROUND: Chronic urticaria (CU) is a common disorder characterized by recurrent episodes of urticaria pruritic erythematous lesions, associated with angioedema(1). It affects 0.1% of the population, it is estimated that approximately 15 to 25% of the population will have hives at some point in their lives.(2) About 80% of UC patients are diagnosed as idiopathic chronic urticaria and that no cause is identified, 3 experiencing deterioration in their quality of life affecting your work, social relationships, schemes requiring multiple medications and doses higher than usual. This study proposes Omalizumab (anti-IgE humanized antibody) as a treatment for Refractory Chronic Urticaria (RCU) OBJECT: Demonstrate Omalizumab's effectiveness in the treatment of Refractory Chronic Urticaria. METHODS: A clinical study, was carried out to evaluate the effectiveness of the Omalizumab's treatment on RCU diagnosed patient, including male and female patients ages 12 to 50 diagnosed with RCU, with Scorad higher tan 30 points. We made a questionnaire to know about the patient's family background, skin symptoms beginning, administration of drugs such sistemic steroids, inmunosupresors, calceurine inhibitors, presence of inmunotherapy and age of start. Omalizumab was administered on doses according patient's weight and IgE levels, bimonthly or monthly according to treatment guides. Severeness level was calculated with scorad every 1 month, with IgE seric level measurement and life quality questionnaire. RESULTS: 5 patients diagnosed with RCU were included in the group of Omalizumab and 5 patients in the control group (placebo). All patients were female. A gradual decrease on the life quality score and in Score, with a significant P under 0.05 was observed on all patients treated with omalizumab compared with patient in the group with placebo. CONCLUSIONS: Treatment with Omalizumab progressively decreases the severeness level on RCU, with a significant improvement on the patient's life quality.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
movoi完成签到 ,获得积分10
1秒前
1秒前
CipherSage应助秋夕未见君采纳,获得10
1秒前
痴情的乐松完成签到 ,获得积分10
2秒前
维尼完成签到 ,获得积分10
2秒前
2秒前
centlay发布了新的文献求助10
3秒前
NexusExplorer应助陈冠羽采纳,获得10
3秒前
4秒前
6秒前
cjsz_kiteng完成签到,获得积分10
7秒前
ning完成签到 ,获得积分10
8秒前
APPLE0327发布了新的文献求助10
8秒前
9秒前
9秒前
10秒前
10秒前
yingying发布了新的文献求助10
11秒前
11秒前
柚米完成签到,获得积分10
12秒前
高兴颤完成签到,获得积分10
12秒前
devil完成签到,获得积分10
13秒前
13秒前
荒林发布了新的文献求助10
13秒前
nsywhh2完成签到,获得积分10
14秒前
屈奕发布了新的文献求助10
14秒前
陈冠羽发布了新的文献求助10
15秒前
优美的冰巧完成签到 ,获得积分10
16秒前
鲤鱼忆丹发布了新的文献求助10
17秒前
仇霁完成签到,获得积分10
17秒前
浮生发布了新的文献求助10
18秒前
霸气初蝶完成签到,获得积分20
20秒前
荒林完成签到,获得积分20
21秒前
大力的契发布了新的文献求助10
21秒前
22秒前
科目三应助dd采纳,获得10
22秒前
脑洞疼应助ll采纳,获得30
22秒前
23秒前
yl完成签到,获得积分10
23秒前
活力的问安完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7740611
求助须知:如何正确求助?哪些是违规求助? 9289226
关于积分的说明 20194730
捐赠科研通 7318813
什么是DOI,文献DOI怎么找? 3306487
关于科研通互助平台的介绍 2458764
邀请新用户注册赠送积分活动 2316626